{"transactions":[{"id":281762,"issuer":{"id":13927,"kind":"organization","name":"BARRIER THERAPEUTICS INC","symbol":"BTRX"},"owners":[{"id":2722,"kind":"organization","name":"JOHNSON & JOHNSON","symbol":"JNJ","position":1,"cik":"0000200406","reported_name":"JOHNSON & JOHNSON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11151,"kind":"organization","name":"Johnson & Johnson Innovation - JJDC, Inc.","position":2,"cik":"0000924020","reported_name":"JOHNSON & JOHNSON DEVELOPMENT CORP ET AL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13928,"kind":"organization","name":"Johnson & Johnson Consumer Companies, Inc.","position":3,"cik":"0001290934","reported_name":"Johnson & Johnson Consumer Companies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13929,"kind":"organization","name":"Janssen Pharmaceutica Products, L.P.","position":4,"cik":"0001290895","reported_name":"Janssen Pharmaceutica Products, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2005-02-15T22:09:54.000Z","date":"2005-02-15","kind":"sale","acquired":false,"shares":694327,"price":19.5,"value":13539376.5,"ownership":{"direct":false,"nature":"By three subsidiaries"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person:  Johnson & Johnson Development Corporation (\"JJDC\") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. (\"JJCC\") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. (\"JPP\") (selling 508,689 shares of Common Stock).  Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person:  Johnson & Johnson Development Corporation (\"JJDC\") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. (\"JJCC\") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. (\"JPP\") (selling 508,689 shares of Common Stock).  Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock."}],"balance_after":3753749,"source":{"system":"sec-edgar","filing":"0000904454-05-000123","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/200406/000090445405000123/edgar.xml","form_type":"4"}},{"id":290406,"issuer":{"id":13927,"kind":"organization","name":"BARRIER THERAPEUTICS INC","symbol":"BTRX"},"owners":[{"id":2722,"kind":"organization","name":"JOHNSON & JOHNSON","symbol":"JNJ","position":1,"cik":"0000200406","reported_name":"JOHNSON & JOHNSON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13929,"kind":"organization","name":"Janssen Pharmaceutica Products, L.P.","position":2,"cik":"0001290895","reported_name":"Janssen Pharmaceutica Products, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13928,"kind":"organization","name":"Johnson & Johnson Consumer Companies, Inc.","position":3,"cik":"0001290934","reported_name":"Johnson & Johnson Consumer Companies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11151,"kind":"organization","name":"Johnson & Johnson Innovation - JJDC, Inc.","position":4,"cik":"0000924020","reported_name":"JOHNSON & JOHNSON DEVELOPMENT CORP ET AL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2004-06-04T14:16:34.000Z","date":"2004-04-28","kind":"exercise","acquired":false,"shares":512820,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person:  Johnson & Johnson Development Corporation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers."}],"balance_after":0,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0000200406-04-000085","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/200406/000020040604000085/edgar.xml","form_type":"4/A","original_submission_date":"2004-04-30"}},{"id":290405,"issuer":{"id":13927,"kind":"organization","name":"BARRIER THERAPEUTICS INC","symbol":"BTRX"},"owners":[{"id":2722,"kind":"organization","name":"JOHNSON & JOHNSON","symbol":"JNJ","position":1,"cik":"0000200406","reported_name":"JOHNSON & JOHNSON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13929,"kind":"organization","name":"Janssen Pharmaceutica Products, L.P.","position":2,"cik":"0001290895","reported_name":"Janssen Pharmaceutica Products, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13928,"kind":"organization","name":"Johnson & Johnson Consumer Companies, Inc.","position":3,"cik":"0001290934","reported_name":"Johnson & Johnson Consumer Companies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11151,"kind":"organization","name":"Johnson & Johnson Innovation - JJDC, Inc.","position":4,"cik":"0000924020","reported_name":"JOHNSON & JOHNSON DEVELOPMENT CORP ET AL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2004-06-04T14:16:34.000Z","date":"2004-04-28","kind":"exercise","acquired":false,"shares":50000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person:  Johnson & Johnson Development Corporation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers."}],"balance_after":0,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0000200406-04-000085","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/200406/000020040604000085/edgar.xml","form_type":"4/A","original_submission_date":"2004-04-30"}},{"id":290404,"issuer":{"id":13927,"kind":"organization","name":"BARRIER THERAPEUTICS INC","symbol":"BTRX"},"owners":[{"id":2722,"kind":"organization","name":"JOHNSON & JOHNSON","symbol":"JNJ","position":1,"cik":"0000200406","reported_name":"JOHNSON & JOHNSON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13929,"kind":"organization","name":"Janssen Pharmaceutica Products, L.P.","position":2,"cik":"0001290895","reported_name":"Janssen Pharmaceutica Products, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13928,"kind":"organization","name":"Johnson & Johnson Consumer Companies, Inc.","position":3,"cik":"0001290934","reported_name":"Johnson & Johnson Consumer Companies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11151,"kind":"organization","name":"Johnson & Johnson Innovation - JJDC, Inc.","position":4,"cik":"0000924020","reported_name":"JOHNSON & JOHNSON DEVELOPMENT CORP ET AL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2004-06-04T14:16:34.000Z","date":"2004-04-28","kind":"exercise","acquired":false,"shares":8333333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person:  Johnson & Johnson Consumer Companies, Inc.; Janssen Pharmaceutica Products, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers."}],"balance_after":0,"derivative":{"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0000200406-04-000085","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/200406/000020040604000085/edgar.xml","form_type":"4/A","original_submission_date":"2004-04-30"}},{"id":290403,"issuer":{"id":13927,"kind":"organization","name":"BARRIER THERAPEUTICS INC","symbol":"BTRX"},"owners":[{"id":2722,"kind":"organization","name":"JOHNSON & JOHNSON","symbol":"JNJ","position":1,"cik":"0000200406","reported_name":"JOHNSON & JOHNSON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13929,"kind":"organization","name":"Janssen Pharmaceutica Products, L.P.","position":2,"cik":"0001290895","reported_name":"Janssen Pharmaceutica Products, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":13928,"kind":"organization","name":"Johnson & Johnson Consumer Companies, Inc.","position":3,"cik":"0001290934","reported_name":"Johnson & Johnson Consumer Companies, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":11151,"kind":"organization","name":"Johnson & Johnson Innovation - JJDC, Inc.","position":4,"cik":"0000924020","reported_name":"JOHNSON & JOHNSON DEVELOPMENT CORP ET AL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2004-06-04T14:16:34.000Z","date":"2004-04-28","kind":"exercise","acquired":true,"shares":4448076,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person:  Johnson & Johnson Consumer Companies, Inc. (1,016,666 shares of Common Stock); Janssen Pharmaceutica Products, L.P. (3,150,000 shares Common Stock); Johnson & Johnson Development Corporation (281,410 shares Common Stock)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person:  Johnson & Johnson Consumer Companies, Inc. (1,016,666 shares of Common Stock); Janssen Pharmaceutica Products, L.P. (3,150,000 shares Common Stock); Johnson & Johnson Development Corporation (281,410 shares Common Stock)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers."}],"balance_after":4448076,"source":{"system":"sec-edgar","filing":"0000200406-04-000085","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/200406/000020040604000085/edgar.xml","form_type":"4/A","original_submission_date":"2004-04-30"}}]}